No Data
No Data
Hainan Shuangcheng Pharmaceuticals (002693.SZ) intends to sign a technical service contract with Qingpu Biology for the development of the QP002 gel project.
On July 19th, Gelunhui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) plans to sign a "Technical Services Contract" with its affiliated company, Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as "Qingpu Biotech" or "Party A"), entrusting the company to carry out technical research on the QP002 gel project on the company's premises. Qingpu Biotech will pay a technical service fee and compensation of RMB 4.8 million. The company will accept the commission to carry out the technical service work on this project.
Shuangcheng Pharma Gets Regulatory Nod to Amend Production Scope for Triptorelin Acetate Injection
Hainan Shuangcheng Pharmaceuticals: Hainan Shuangcheng Pharmaceuticals Co., Ltd. released its performance forecast for the first half of 2024.
Hainan Shuangcheng Pharmaceuticals (002693.SZ) released 32 million shares from the controlling shareholder's pledge, accounting for 7.68% of the total share capital.
Hainan Shuangcheng Pharmaceuticals (002693.SZ) has issued an announcement that it recently received notification from the company's controlling shareholder, Hainan Shuangcheng Investment Co., Ltd...
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Production license of Ningbo Shuangcheng Pharmaceuticals changed, involving an increase in entrusted production information.
On June 20th, Gelunhui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that its holding subsidiary, Ningbo Shuangcheng Pharmaceuticals Co., Ltd. ("Ningbo Shuangcheng"), had recently obtained a Drug Production License reissued by the Zhejiang Provincial Drug Administration. The matters involved in this change are: authorizing Ningbo Shuangcheng to add the name of the entrusted enterprise as Zhejiang Heze Pharmaceutical Technology Co., Ltd., with a production/registration address at Room 201, Building 4, No. 101, First Street, Xiasan Street, Qiantang District, Hangzhou City, Zhejiang Province, and the drug name as KY-XES with no approval number, registered in conjunction with the application (for registration application only).
Hainan Shuangcheng Pharmaceuticals' Q1 2024 Financial Report: Deep Dive into Financial Data.
Hainan Shuangcheng Pharmaceuticals (stock code: 002693) is a company that focuses on the research and development of chemically synthesized polypeptide drugs and is committed to promoting innovation in the polypeptide drug industry. The company occupies an important position in the medical industry, especially in the field of polypeptide drugs. In recent years, despite the challenges of economic downturn and policy adjustment in the medical industry, it has also ushered in new development opportunities. In 2023, the country will introduce multiple policies aimed at deepening the linkage reform of medicine, medical care, and medical insurance and promoting the healthy development of the industry. In particular, various guiding principles and management methods issued by the National Medical Products Administration provide development and business opportunities for Hainan Shuangcheng Pharmaceuticals in the future.
No Data